Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).
Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | EU | Carcinoma, Transitional Cell | Merck Europe Bv | 2017-03-23 | Chordoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse; Papillomavirus Infections; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Anus Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Carcinoma, Merkel Cell; Solid tumours | Details |
Envafolimab | KN-035; ASC-22; KN035; ASC22 | Approved | Suzhou Alphamab Co Ltd | Mainland China | Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer | 3d Medicines (Sichuan) Co Ltd | 2021-11-25 | Shock, Septic; Solid tumours; Liver Neoplasms; Hepatitis B, Chronic; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Sepsis; Microsatellite instability-high cancer; Colorectal Neoplasms; Bile Duct Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Durvalumab | 28X28X9-OKV (UNII code); MEDI-4736 | Approved | Medimmune Llc | 英飞凡, Imfinzi | United States | Small Cell Lung Carcinoma | Astrazeneca Uk Ltd | 2018-02-16 | Esophageal Squamous Cell Carcinoma; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Multiple Myeloma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms; Kidney Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma; Head and Neck Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Papillomavirus Infections; Urinary Bladder Neoplasms; Digestive System Neoplasms | Details |
Sugemalimab | WBP-3155; CS-1001 | Approved | Cstone Pharmaceuticals (Suzhou) Co Ltd | 择捷美 | Mainland China | Carcinoma, Non-Small-Cell Lung | Cstone Pharmaceuticals (Suzhou) Co Ltd | 2021-12-20 | Prostatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma; Lymphoma, T-Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Ovarian Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
Atezolizumab | RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A | Approved | Genentech Inc | 泰圣奇, Tecentriq | Mainland China | Carcinoma, Non-Small-Cell Lung | Roche (China) Holding Ltd | 2016-05-18 | Uterine Neoplasms; Microsatellite Instability; Colorectal Neoplasms; Urologic Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Thymoma; Neoplasms, Unknown Primary; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Sarcoma; Gallbladder Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Urogenital Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Liposarcoma, Myxoid; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Transitional Cell; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Pancreatic Neoplasms; Liver Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; P | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech | Carcinoma, Non-Small-Cell Lung | Details |
FH-2001 | FH-2001 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical Development Ltd | Solid tumours | Details |
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | Phase 1 Clinical | The Second Hospital Of Nanjing Medical University | Carcinoma, Hepatocellular | Details | |
TT-00420/Atezolizumab | Phase 1 Clinical | Yaojie Ankang (Nanjing) Technology Co Ltd | Gastrointestinal Neoplasms | Details | |
FS 118 | FS-118 | Phase 2 Clinical | Merck Serono, F-Star | Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis | Details |
GT-90008 | GS-19-PLB-1C; GT-90008; GS-19 | Phase 1 Clinical | Suzhou Kintor Pharmaceuticals Inc | Solid tumours | Details |
BMS-936559 | MDX-1105; BMS-936559 | Phase 3 Clinical | Bristol-Myers Squibb Company | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
CK-301 | CK-301 | Phase 1 Clinical | Dana-Farber Cancer Institute | Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
IMM-2510 | IMM-2510 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
Q-1802 | Q-1802 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
ACT-001 | ACT-001 | Phase 2 Clinical | Accendatech | Glioblastoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 2 Clinical | Numab Therapeutics Ag, Cstone Pharmaceuticals | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Emdifen | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences | Solid tumours | Details | |
ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio | Solid tumours | Details |
Garivulimab | BGB-A333 | Phase 1 Clinical | Beigene Ltd | Solid tumours; Neoplasms | Details |
TQB-2450 | APL-502; CBT-502; TQ-B2450 | Phase 3 Clinical | Cbt | Stroke; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Liver Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Genital Diseases, Female; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Lymphoma, B-Cell; Solid tumours | Details |
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma | Details |
SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
LY-3415244 | LY-3415244 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Neoplasms | Details |
ABSK-043 | ABSK043 | Phase 1 Clinical | Abbisko Therapeutics | Solid tumours; Neoplasms | Details |
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
HB-0025 | HB0025 | Phase 1 Clinical | Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part | Details |
GR-1405 | GR-1405 | Phase 3 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma | Details |
GS-4224 | GS-4224 | Phase 1 Clinical | Gilead Sciences Inc | Solid tumours; Hepatitis B | Details |
Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
PRS-344 | PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc, Laboratoires Servier | Solid tumours | Details |
GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours | Details |
Erfonrilimab | KN-046; KN046 | Phase 3 Clinical | Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
PF-07257876 | Phase 1 Clinical | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | ||
FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics | Solid tumours | Details |
Sudubrilimab | HS-636 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Triple Negative Breast Neoplasms; Primary mediastinal B cell lymphoma | Details |
Human source and Fc engineered monoclonal antibody (MabSpace) | MSB-2311 | Phase 1 Clinical | Mabspace Biosciences Co Ltd | Solid tumours | Details |
BMS-986189 | BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 | Phase 1 Clinical | Bristol-Myers Squibb Company | Sepsis | Details |
ALPN-202 | ALPN-202 | Phase 1 Clinical | Alpine Immune Sciences | Solid tumours; Lymphoma | Details |
IMM2505 | IMM2505 | Phase 1 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours | Details |
Opucolimab | HLX-20 | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Solid tumours; Neoplasms | Details |
BR-102 | BR102 | Phase 1 Clinical | Solid tumours | Details | |
89Zr-KN035(Wuxi No. 4 People's Hospital) | Clinical | Wuxi No. 4 People | Solid tumours | Details | |
QLF31907 | QLF31907; QLF-31907 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
Carrizumab | Phase 2 Clinical | Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details | ||
IMC-001 | IMC-001; STI-3031; STI-A1015 | Phase 2 Clinical | Sorrento Therapeutics | Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
TJ-L14B | ABL-503; TJ-L14B/ABL503; ABL503 | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms | Details | |
PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Biotheus Inc | Solid tumours; Lung Neoplasms | Details |
MT-6402 | Phase 1 Clinical | Molecular Templates | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | |
MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms | Details |
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd | Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms | Details | |
PM-1003 | PM1003 | Phase 2 Clinical | Biotheus Inc | Solid tumours | Details |
MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus | Solid tumours | Details |
IGV-001 | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
FS-222 | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Neoplasm Metastasis | Details |
18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Head and Neck Neoplasms | Details | |
Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd | Solid tumours | Details |
IBI-318(Innovent Biologics/Eli Lilly And Company) | LY-3434172; LY3434172; IBI-318 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | Imugene Ltd, City Of Hope National Medical Center | Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
GNC-035 quadr-specific antibody(baili) | GNC-035 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Manelimab | BCD-135 | Phase 1 Clinical | Biocad | Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics | Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma | Details |
Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ATG-101 | ATG-101 | Phase 1 Clinical | Antengene Corporation Co Ltd | Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin | Details |
AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biomedical Technology Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
TST-005 | TST-005; TST005 | Phase 1 Clinical | Mabspace Biosciences Co Ltd | Neoplasms | Details |
ADG-104 | ADG-104; ADG104 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc | Neoplasms | Details |
SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Lymphoma | Details |
TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung | Details |
INBRX-105 | ES101; INBRX-105 | Phase 2 Clinical | Inhibrx | Solid tumours; Thoracic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
JS-003 | JS-003 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours | Details |
RC-98 | RC-98; RC98 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours | Details |
99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
GNC-038 | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Simridarlimab | IBI-322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Hematologic Neoplasms; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute | Details |
MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours | Details |
6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Neoplasms | Details |
INCB-086550 | INCB-086550; INCB-86550 | Phase 2 Clinical | Incyte Corp | Solid tumours; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
RG-6084 | RG-6084; RO-7191863 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B | Details |
TQB-2858 | TQB-2858 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Pancreatic Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Cosibelimab | TG-1501; CK-301 | Phase 3 Clinical | Tg Therapeutics | Lymphoma; Carcinoma, Non-Small-Cell Lung | Details |
CA-170 | AUPM-170; CA-170 | Phase 1 Clinical | Aurigene | Solid tumours | Details |
Acasunlimab | GEN1046; BNT-311; DuoBody-PD-L1x4-1BB; PD-L1x4-1BB | Phase 2 Clinical | Biontech Se, Genmab | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
SGN-PDL1V | SGN-PDL1V | Phase 1 Clinical | Seagen Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
BAT-7104 | BAT-7104 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
Retlirafusp alfa | SHR-1701 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
LBL-024 | LBL024; LBL-024 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Solid tumours | Details |
ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Solid tumours; Neoplasms | Details |
KD-033 | KD-033 | Phase 1 Clinical | Takeda Pharma | Solid tumours | Details |
Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
QL-415 | QL-415 | Phase 1 Clinical | Neoplasms | Details | |
QL-301 | QL-301 | Phase 1 Clinical | Neoplasms | Details | |
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details |
This web search service is supported by Google Inc.